# OnCo record nct02637531 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02637531/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02637531", "NCT02637531" ;
  schema:name "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549"@en ;
  schema:description "A phase 1 trial of Eganelisib run by Infinity Pharmaceuticals, Inc., of unknown status on the registry."@en ;
  schema:url <https://onco.cc/trials/nct02637531/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02637531> ;
  onco:status "historic" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/adrenocortical/>, <https://onco.cc/cancers/mesothelioma/> ;
  onco:drugs <https://onco.cc/drugs/eganelisib/> ;
  onco:companies <https://onco.cc/companies/stelexis-biosciences/> .